TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

<div>The odds ratio of mPFS treated with combination therapy with bevacizumab or TAS-102 monotherapy as the experiment group.</div>

Gastroenterology Research and Practice

Figure 7: TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer 